



The COVID-19 & Cancer Consortium

Patients with cancer have a unique risk profile in the SARS-CoV-2 pandemic. Many patients, especially those actively on treatment, have high levels of contact with the health care system, putting them at an increased risk for SARS-CoV-2 infection and development of COVID-19. Additionally, many if not all patients with cancer are immunocompromised, through the immunosuppressive effects of anti-cancer drugs, supportive medications such as steroids, and cancer itself. Many patients with cancer are over 60 years old, putting them in the highest-risk category for COVID-19-related morbidity and mortality.

Given an acute lack of knowledge and concern for extreme vulnerability, the **COVID-19 and Cancer Consortium (CCC19)** was formed on March 15, 2020. There are now **more than 100 participating sites** from the United States, Canada, and Mexico. Many institutional members are large NCI-designated Comprehensive Cancer Centers; large networks of community practices including several NCORP sites are also represented. ***The driving goal of the CCC19 consortium is to collect and disseminate prospective, granular, uniformly organized information on people with cancer who are diagnosed with COVID-19 – at scale and as rapidly as possible.***

Website: <https://ccc19.org/>

Email: contact@ccc19.org

Clinical Trial ID: NCT04354701

Steering Committee

Toni K. Choueiri, MD *Dana-Farber Cancer Institute*

Narjust Florez, MD *Dana-Farber Cancer Institute*

Dimitrios Farmakiotis, MD, FACP, FIDSA *Brown University/Lifespan Cancer Institute*

Petros Grivas, MD, PhD *Fred Hutchinson Cancer Center*

Gilberto de Lima Lopes, Jr., MD, MBA, FAMS, FASCO *Sylvester Comprehensive Cancer Center*

Corrie A. Painter, PhD *Broad Institute of MIT and Harvard*

Solange Peters, MD, PhD *Centre Hospitalier Universitaire Vaudois*

Sonya Reid, MD, MPH *Vanderbilt-Ingram Cancer Center*

Dimpy P. Shah, MD, PhD *Mays Cancer Center at UT Health San Antonio*

Michael A. Thompson, MD, PhD, FASCO *Tempus*

Jeremy L. Warner, MD, MS, FAMIA, FASCO *Legorreta Cancer Center/Lifespan Cancer Institute*

Scientific Executive Committee

Jill S. Barnholtz-Sloan, PhD *National Cancer Institute*

Donna R. Rivera, PharmD, MSc *U.S. Food and Drug Administration*

Project Coordinator

Sanjay Mishra, MS, PhD *Brown University/Lifespan Cancer Institute*




Image source: NCI (public domain)

Participating Institutions (current as of February 28, 2023)

NCI-designated* Comprehensive Cancer Center

NCI-designated Cancer Center

Platinum Tier Institutions

These sites are recognized for outstanding overall and ongoing contributions to the CCC19 registry.

- Brown University/Lifespan Cancer Institute (Providence, RI, USA)
- Columbia University/Herbert Irving Comprehensive Cancer Center⁴ (New York, NY, USA)
- Dana-Farber Cancer Institute¹⁺ (Boston, MA, USA)
- Hartford HealthCare Cancer Institute (Hartford, CT, USA)
- Henry Ford Cancer Institute, Henry Ford Hospital (Detroit, MI, USA)
- Instituto Nacional de Cancerología (Ciudad de México, CDMX, Mexico)
- Loma Linda University Cancer Center (Loma Linda, CA, USA)
- Mount Auburn Hospital (Cambridge, MA, USA)
- Roswell Park Comprehensive Cancer Center (Buffalo, NY, USA)
- University of California San Diego/Moores Cancer Center (La Jolla, CA, USA)
- University of Cincinnati Cancer Center (Cincinnati, OH, USA)
- University of Kansas Medical Center⁴ (Kansas City, KS, USA)
- University of Michigan/Rogel Cancer Center (Ann Arbor, MI, USA)
- Virtua Health (NJ, USA)

Gold Tier Institutions

These sites are recognized for substantial overall and ongoing contributions to the CCC19 registry.



Advocate Aurora Health³⁺ (WI, USA)
Albert Einstein/Montefiore Medical Center⁴ (Bronx, NY, USA)
Cleveland Clinic² (Cleveland, OH, USA)
Duke University Medical Center/Duke Cancer Institute (Durham, NC, USA)
Emory University/Winship Cancer Institute (Atlanta, GA, USA)
Fred Hutchinson Cancer Research Center/University of Washington/Seattle Cancer Care Alliance⁺ (Seattle, WA, USA)
George Washington University (Washington, DC, USA)
Loyola University Medical Center (Maywood, IL, USA)
McGill University Health Centre (Montreal, QC, Canada)
Medical College of Wisconsin (Milwaukee, WI, USA)
Mount Sinai/Tisch Cancer Institute (New York, NY, USA)
Northwest Medical Specialties (Tacoma, WA, USA)
Ohio State University Comprehensive Cancer Center (Columbus, OH, USA)
Oregon Health & Sciences University/Knight Cancer Institute (Portland, OR, USA)
Penn State Cancer Institute (Hershey, PA, USA)
Penn State Health St. Joseph Cancer Center (Reading, PA, USA)
Segal Cancer Centre, Jewish General Hospital, McGill University (Montreal, QC, Canada)
Stamford Hospital/Carl & Dorothy Bennett Cancer Center (Stamford, CT, USA)
Stanford University/Stanford Cancer Institute (Palo Alto, CA, USA)
St. Elizabeth Healthcare³ (IN/KY/OH, USA)
Tallahassee Memorial Healthcare (Tallahassee, FL, USA)
Thomas Jefferson University/Sidney Kimmel Cancer Center (Philadelphia, PA, USA)
University of California, San Francisco/Helen Diller Family Comprehensive Cancer Center (San Francisco, CA, USA)
University of Illinois at Chicago (Chicago, IL, USA)
University of Kentucky/Markey Cancer Center (Lexington, KY, USA)
University of Minnesota/Masonic Cancer Center (Minneapolis, MN, USA)
UPMC Western Maryland (Cumberland, MD, USA)
UT Health San Antonio MD Anderson Cancer Center/Mays Cancer Center⁴ (San Antonio, TX, USA)
Vanderbilt University Medical Center/Vanderbilt-Ingram Cancer Center⁺ (Nashville, TN, USA)

Silver Tier Institutions

These sites are recognized for overall and/or ongoing contributions to the CCC19 registry.

Banner MD Anderson Cancer Center (Phoenix, AZ, USA)
Geisinger Health System³ (PA, USA)
Inova Schar Cancer Institute (Fairfax, VA, USA)
Kaiser Permanente Northwest³ (OR/WA, USA)
Lewis Cancer & Research Pavilion @ St. Joseph's/Candler³ (Savannah, GA, USA)
LSU Health Sciences Center – New Orleans/Stanley S. Scott Cancer Center (New Orleans, LA, USA)
Massachusetts General Hospital¹ (Boston, MA, USA)
Mayo Clinic (AZ/FL/MN, USA)
Medical University of South Carolina/Hollings Cancer Center⁴ (Charleston, SC, USA)
Memorial Sloan-Kettering Cancer Center (New York, NY, USA)



Missouri Baptist Medical Center³ (St. Louis, MO, USA)
Moffitt Cancer Center (Tampa, FL, USA)
Providence Cancer Institute (Portland, OR, USA)
Rutgers Cancer Institute of New Jersey (New Brunswick, NJ, USA)
ThedaCare Cancer Care³ (Appleton, WI, USA)
Tufts Medical Center (Boston, MA, USA)
University of Florida Health Cancer Center (Gainesville, FL, USA)
University of Hawai'i Cancer Center⁴ (Honolulu, HI, USA)
University of Iowa/Holden Comprehensive Cancer Center (Iowa City, IA, USA)
University of North Carolina/Lineberger Comprehensive Cancer Center (Chapel Hill, NC, USA)
Washington University in St. Louis/Siteman Cancer Center (St. Louis, MO, USA)

Bronze Tier Institutions

These sites are recognized for contributions to the CCC19 registry.

Baptist Cancer Center⁴ (Memphis, TN, USA)
Baylor College of Medicine/Dan L. Duncan Comprehensive Cancer Center (Houston, TX, USA)
BC Cancer (Vancouver, BC, Canada)
Beth Israel Deaconess Medical Center¹ (Boston, MA, USA)
Centre Hospitalier de l'Université de Montréal (Montreal, QC, Canada)
Centro Médico ABC (Ciudad de México, CDMX, Mexico)
Einstein Healthcare Network (Philadelphia, PA, USA)
Gundersen Health System³ (WI, USA)
Houston Methodist Cancer Center (Houston, TX, USA)
Intermountain Healthcare³ (Salt Lake City, UT, USA)
Mount Carmel Health System³ (Columbus, OH, USA)
Northwestern University/Lurie Cancer Center (Chicago, IL, USA)
Thompson Cancer Survival Center (Knoxville, TN, USA)
Tripler Army Medical Center (Honolulu, HI, USA)
University Hospitals, Cleveland² (Cleveland, OH, USA)
University of California at Davis/UC Davis Comprehensive Cancer Center (Davis, CA, USA)
University of Colorado Cancer Center (Aurora, CO, USA)
University of Miami/Sylvester Comprehensive Cancer Center⁺ (Miami, FL, USA)
Virginia Mason Cancer Institute (Seattle, WA, USA)
Wake Forest Baptist Comprehensive Cancer Center (Winston-Salem, NC, USA)
Wayne State University/Barbara Ann Karmanos Cancer Institute (Detroit, MI, USA)
Weill Cornell Medicine/Meyer Cancer Center (New York, NY, USA)
WellSpan Health (PA, USA)
Wentworth-Douglass Hospital (Dover, NH, USA)
Willis-Knighton Cancer Center⁴ (Shreveport, LA, USA)
Yale New Haven Health/Smilow Cancer Hospital (New Haven, CT, USA)

Unlisted Institutions

These sites have either not yet contributed to the CCC19 registry or have opted out of public recognition.

Barrow Neurological Institute (Phoenix, AZ, USA)
Boston Medical Center (Boston, MA, USA)
City of Hope Comprehensive Cancer Center (Duarte, CA, USA)



Cook County Hospital⁴ (Chicago, IL, USA)

Georgetown University/Georgetown Lombardi Comprehensive Cancer Center (Washington, DC, USA)

Hamilton Health Sciences (Hamilton, ON, Canada)

HCA Houston Healthcare North Cypress (Houston, TX, USA)

Hospital General de México (Ciudad de México, CDMX, Mexico)

Hospital Regional de Alta Especialidad de Ixtapaluca (Mexico State, Mexico)

Johns Hopkins University/Sidney Kimmel Comprehensive Cancer Center (Baltimore, MD, USA)

Kent Hospital/Care New England (Warwick, RI, USA)

MD Anderson Cancer Center (Houston, TX, USA)

MD Anderson Cancer Center at Cooper (Camden, NJ, USA)

Meharry Medical College (Nashville, TN, USA)

Michigan Center of Medical Research³ (Farmington Hills, MI, USA)

NYU Langone Health/Perlmutter Cancer Center (New York, NY, USA)

Parkview Cancer Institute/Parkview Research Center (Fort Wayne, IN, USA)

Renown Regional Medical Center (Reno, NV, USA)

Rush University Medical Center³ (Chicago, IL, USA)

SUNY Downstate Health Sciences University (Brooklyn, NY, USA)

UCLA Jonsson Comprehensive Cancer Center (Los Angeles, CA, USA)

University of Alabama/O'Neal Comprehensive Cancer Center (Birmingham, AL, USA)

University of Arkansas for Medical Sciences (Little Rock, AR, USA)

University of Chicago Comprehensive Cancer Center (Chicago, IL, USA)

University of Connecticut (Farmington, CT, USA)

University of Louisville/James Graham Brown Cancer Center (Louisville, KY, USA)

University of Maryland/Marlene and Stewart Greenebaum Comprehensive Cancer Center (College Park, MD, USA)

University of Nebraska Medical Center/Fred and Pamela Buffett Cancer Center (Omaha, NE, USA)

University of Rochester Medical Center (Rochester, NY, USA)

University of Texas Southwestern Medical Center/Harold C. Simmons Comprehensive Cancer Center (Dallas, TX, USA)

University of Utah/Huntsman Cancer Institute (Salt Lake City, UT, USA)

University of Wisconsin/Carbone Cancer Center (Madison, WI, USA)

Vidant Medical Center, East Carolina University (Greenville, NC, USA)

¹Under the umbrella of Dana Farber/Harvard Cancer Center

²Under the umbrella of Case Comprehensive Cancer Center

³NCI Community Oncology Research Program (NCORP) Community Site

⁴NCI Community Oncology Research Program (NCORP) Minority/Underserved Community Site

*Equivalent designation outside of United States is per local country criteria

*Founding member of the COVID-19 and Cancer Consortium



Bibliography

Protocol and Governance Overview

COVID-19 and Cancer Consortium. A Systematic Framework to Rapidly Obtain Data on Patients with Cancer and COVID-19: CCC19 Governance, Protocol, and Quality Assurance. *Cancer Cell*. 2020 Dec 14;38(6):761-766. doi: [10.1016/j.ccell.2020.10.022](https://doi.org/10.1016/j.ccell.2020.10.022). PMID: 33176160; PMCID: PMC7598547.

Original Research (- contributed equally)*

1. Kuderer NM*, Choueiri TK*, Shah DP*, Shyr Y*, Rubinstein SM, Rivera DR, Shete S, Hsu CY, Desai A, de Lima Lopes G Jr, Grivas P, Painter CA, Peters S, Thompson MA, Bakouny Z, Batist G, Bekaii-Saab T, Bilen MA, Bouganim N, Larroya MB, Castellano D, Del Prete SA, Doroshov DB, Egan PC, Elkrief A, Farmakiotis D, Flora D, Galsky MD, Glover MJ, Griffiths EA, Gulati AP, Gupta S, Hafez N, Halfdanarson TR, Hawley JE, Hsu E, Kasi A, Khaki AR, Lemmon CA, Lewis C, Logan B, Masters T, McKay RR, Mesa RA, Morgans AK, Mulcahy MF, Panagiotou OA, Peddi P, Pennell NA, Reynolds K, Rosen LR, Rosovsky R, Salazar M, Schmidt A, Shah SA, Shaya JA, Steinharter J, Stockerl-Goldstein KE, Subbiah S, Vinh DC, Wehbe FH, Weissmann LB, Wu JT, Wulff-Burchfield E, Xie Z, Yeh A, Yu PP, Zhou AY, Zubiri L, Mishra S, Lyman GH*, Rini BI*, Warner JL*; COVID-19 and Cancer Consortium. **Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study.** *The Lancet*. 2020 Jun 20;395(10241):1907-1918. doi: [10.1016/S0140-6736\(20\)31187-9](https://doi.org/10.1016/S0140-6736(20)31187-9). PMID: 32473681; PMCID: PMC7255743.
2. Rivera DR*, Peters S*, Panagiotou OA, Shah DP, Kuderer NM, Hsu CY, Rubinstein SM, Lee BJ, Choueiri TK, de Lima Lopes G Jr, Grivas P, Painter CA, Rini BI, Thompson MA, Arcobello J, Bakouny Z, Doroshov DB, Egan PC, Farmakiotis D, Fecher LA, Friese CR, Galsky MD, Goel S, Gupta S, Halfdanarson TR, Halmos B, Hawley JE, Khaki AR, Lemmon CA, Mishra S, Olszewski AJ, Pennell NA, Puc MM, Revankar SG, Schapira L, Schmidt A, Schwartz GK, Shah SA, Wu JT, Xie Z, Yeh AC, Zhu H, Shyr Y*, Lyman GH*, Warner JL*; COVID-19 and Cancer Consortium. **Utilization of COVID-19 Treatments and Clinical Outcomes among Patients with Cancer: A COVID-19 and Cancer Consortium (CCC19) Cohort Study.** *Cancer Discovery*. 2020 Oct;10(10):1514-1527. doi: [10.1158/2159-8290.CD-20-0941](https://doi.org/10.1158/2159-8290.CD-20-0941). PMID: 32699031; PMCID: PMC7541683.
3. Grivas P*, Khaki AR*, Wise-Draper TM*, French B*, Hennessy C, Hsu CY, Shyr Y, Li X, Choueiri TK, Painter CA, Peters S, Rini BI, Thompson MA, Mishra S, Rivera DR, Acoba JD, Abidi MZ, Bakouny Z, Bashir B, Bekaii-Saab T, Berg S, Bernicker EH, Bilen MA, Bindal P, Bishnoi R, Bouganim N, Bowles DW, Cabal A, Caimi PF, Chism DD, Crowell J, Curran C, Desai A, Dixon B, Doroshov DB, Durbin EB, Elkrief A, Farmakiotis D, Fazio A, Fecher LA, Flora DB, Friese CR, Fu J, Gadgeel SM, Galsky MD, Gill DM, Glover MJ, Goyal S, Grover P, Gulati S, Gupta S, Halabi S, Halfdanarson TR, Halmos B, Hausrath DJ, Hawley JE, Hsu E, Huynh-Le M, Hwang C, Jani C, Jayaraj A, Johnson DB, Kasi A, Khan H, Koshkin VS, Kuderer NM, Kwon DH, Lammers PE, Li A, Loaiza-Bonilla A, Low CA, Lustberg MB, Lyman GH, McKay RR, McNair C, Menon H, Mesa RA, Mico V, Mundt D, Nagaraj G, Nakasone ES, Nakayama J, Nizam A, Nock NL, Park C, Patel JM, Patel KG, Peddi P, Pennell NA, Piper-Vallillo AJ, Puc M, Ravindranathan D, Reeves ME, Reuben DY, Rosenstein L, Rosovsky RP, Rubinstein SM, Salazar M, Schmidt AL, Schwartz GK, Shah MR, Shah SA, Shah C, Shaya JA, Singh SRK, Smits M, Stockerl-Goldstein KE, Stover DG, Streckfuss M, Subbiah S, Tachiki L, Tadesse E, Thakkar A, Tucker MD, Verma AK, Vinh DC, Weiss M, Wu JT, Wulff-Burchfield E, Xie Z, Yu PP, Zhang T, Zhou AY, Zhu H, Zubiri L, Shah DP*, Warner JL*, Lopes G*. **Association of clinical factors and recent anticancer therapy with COVID-19 severity among patients with cancer: a report from the COVID-19 and Cancer Consortium.** *Annals of Oncology*. 2021 Jun;32(6):787-800. doi: [10.1016/j.annonc.2021.02.024](https://doi.org/10.1016/j.annonc.2021.02.024). PMID: 33746047; PMCID: PMC7972830.



4. Thompson MA*, Henderson JP*, Shah PK, Rubinstein SM, Joyner MJ, Choueiri TK, Flora DB, Griffiths EA, Gulati AP, Hwang C, Koshkin VS, Papadopoulos EB, Robilotti EV, Su CT, Wulff-Burchfield EM, Xie Z, Yu PP, Mishra S, Senefeld JW, Shah DP*, Warner JL*; COVID-19 and Cancer Consortium. **Association of Convalescent Plasma Therapy With Survival in Patients With Hematologic Cancers and COVID-19.** *JAMA Oncology.* 2021 Aug;7(8):1167–75. doi: [10.1001/jamaoncol.2021.1799](https://doi.org/10.1001/jamaoncol.2021.1799). PMID: 34137799; PMCID: PMC8377563.
5. Li A, Kuderer NM, Hsu CY, Shyr Y, Warner JL, Shah DP, Kumar V, Shah S, Kulkarni AA, Fu J, Gulati S, Zon RL, Li M, Desai A, Egan PC, Bakouny Z, Kc D, Hwang C, Akpan IJ, McKay RR, Girard J, Schmidt AL, Halmos B, Thompson MA, Patel JM, Pennell NA, Peters S, Elshoury A, de Lima Lopes G, Stover DG, Grivas P, Rini BI, Painter CA, Mishra S, Connors JM, Lyman GH, Rosovsky RP; CCC19 consortium. **The CoVID-TE risk assessment model for venous thromboembolism in hospitalized patients with cancer and COVID-19.** *Journal of Thrombosis and Haemostasis.* 2021 Oct;19(10):2522-2532. doi: [10.1111/jth.15463](https://doi.org/10.1111/jth.15463). PMID: 34260813; PMCID: PMC8420489.
6. Schmidt AL*, Tucker MD*, Bakouny Z, Labaki C, Hsu CY, Shyr Y, Armstrong AJ, Beer TM, Bijjula RR, Bilen MA, Connell CF, Dawsey SJ, Faller B, Gao X, Gartrell BA, Gill D, Gulati S, Halabi S, Hwang C, Joshi M, Khaki AR, Menon H, Morris MJ, Puc M, Russell KB, Shah NJ, Sharifi N, Shaya J, Schweizer MT, Steinharter J, Wulff-Burchfield EM, Xu W, Zhu J, Mishra S, Grivas P, Rini BI, Warner JL, Zhang T, Choueiri TK, Gupta S*, McKay RR*. **Association Between Androgen Deprivation Therapy and Mortality Among Patients with Prostate Cancer and COVID-19.** *JAMA Network Open.* 2021 Nov 1;4(11):e2134330. doi: [10.1001/jamanetworkopen.2021.34330](https://doi.org/10.1001/jamanetworkopen.2021.34330). PMID: 34767021; PMCID: PMC8590166.
7. Hawley JE, Sun T, Chism DD, Duma N, Fu JC, Gatson NTN, Mishra S, Nguyen RH, Reid SA, Serrano OK, Singh SRK, Venepalli NK, Bakouny Z, Bashir B, Bilen MA, Caimi PF, Choueiri TK, Dawsey SJ, Fecher LA, Flora DB, Friese CR, Glover MJ, Gonzalez CJ, Goyal S, Halfdanarson TR, Hershman DL, Khan H, Labaki C, Lewis MA, McKay RR, Messing I, Pennell NA, Puc M, Ravindranathan D, Rhodes TD, Rivera AV, Roller J, Schwartz GK, Shah SA, Shaya JA, Streckfuss M, Thompson MA, Wulff-Burchfield EM, Xie Z, Yu PP, Warner JL, Shah DP, French B*, Hwang C*; COVID-19 and Cancer Consortium (CCC19). **Assessment of Regional Variability in COVID-19 Outcomes Among Patients with Cancer in the United States.** *JAMA Network Open.* 2022 Jan 4;5(1):e2142046. doi: [10.1001/jamanetworkopen.2021.42046](https://doi.org/10.1001/jamanetworkopen.2021.42046). PMID: 34982158; PMCID: PMC8728628.
8. Satyanarayana G*, Enriquez KT*, Sun T, Klein EJ, Abidi M, Advani SM, Awosika J, Bakouny Z, Bashir B, Berg S, Bernardes M, Egan PC, Elkrief A, Feldman LE, Friese CR, Goel S, Gomez CG, Grant KL, Griffiths EA, Gulati S, Gupta S, Hwang C, Jain J, Jani C, Kaltsas A, Kasi A, Khan H, Knox N, Koshkin VS, Kwon DH, Labaki C, Lyman GH, McKay RR, McNair C, Nagaraj G, Nakasone ES, Nguyen R, Nonato TK, Olszewski AJ, Panagiotou OA, Puc M, Razavi P, Robilotti EV, Santos-Dutra M, Schmidt AL, Shah DP, Shah SA, Vieira K, Weissmann LB, Wise-Draper TM, Wu U, Wu JT, Choueiri TK, Mishra S, Warner JL, French B, Farmakiotis D. **Coinfections in Patients With Cancer and COVID-19: A COVID-19 and Cancer Consortium (CCC19) Study.** *Open Forum Infectious Diseases.* 2022 Feb 14;9(3):ofac037. doi: [10.1093/ofid/ofac037](https://doi.org/10.1093/ofid/ofac037). PMID: 35198648; PMCID: PMC8860152.
9. Schmidt AL*, Labaki C*, Hsu CY*, Bakouny Z*, Balanchivadze N, Berg SA, Blau S, Daher A, El Zarif T, Friese CR, Griffiths EA, Hawley JE, Hayes-Lattin B, Karivedu V, Latif T, Mavromatis BH, McKay RR, Nagaraj G, Nguyen RH, Panagiotou OA, Portuguese AJ, Puc M, Dutra MS, Schroeder BA, Thakkar A, Wulff-Burchfield EM, Mishra S, Farmakiotis D*, Shyr Y*, Warner JL*, Choueiri TK*; COVID-19 and Cancer Consortium. **COVID-19 Vaccination and Breakthrough Infections in Patients with Cancer.** *Annals of Oncology.* 2022 Mar;33(3):340-346. doi: [10.1016/j.annonc.2021.12.006](https://doi.org/10.1016/j.annonc.2021.12.006). PMID: 34958894; PMCID: PMC8704021.



10. Elkrief A, Hennessy C, Kuderer NM, Rubinstein SM, Wulff-Burchfield E, Rosovsky RP, Vega-Luna K, Thompson MA, Panagiotou OA, Desai A, Rivera DR, Khaki AR, Tachiki L, Lynch RC, Stratton C, Elias R, Batist G, Kasi A, Shah DP, Bakouny Z, Cabal A, Clement J, Crowell J, Dixon B, Friese CR, Fry SL, Grover P, Gulati S, Gupta S, Hwang C, Khan H, Kim SJ, Klein EJ, Labaki C, McKay RR, Nizam A, Pennell NA, Puc M, Schmidt AL, Shahrokni A, Shaya JA, Su CT, Wall S, Williams N, Wise-Draper TM, Mishra S, Grivas P, French B*, Warner JL*, Wildes TM*; COVID-19 and Cancer Consortium. **Geriatric risk factors for serious COVID-19 outcomes among older adults with cancer: a cohort study from the COVID-19 and Cancer Consortium.** *The Lancet Healthy Longevity.* 2022 Mar;3(3):e143-e152. doi: [10.1016/S2666-7568\(22\)00009-5](https://doi.org/10.1016/S2666-7568(22)00009-5). PMID: 35187516; PMCID: PMC8843069.
11. Fu J*, Reid SA*, French B, Hennessy C, Hwang C, Gatson NT, Duma N, Mishra S, Nguyen R, Hawley JE, Singh SRK, Chism DD, Venepalli NK, Warner JL, Choueiri TK, Schmidt AL, Fecher LA, Girard JE, Bilen MA, Ravindranathan D, Goyal S, Wise-Draper TM, Park C, Painter CA, McGlown SM, de Lima Lopes G Jr, Serrano OK*, Shah DP*. **Racial Disparities in COVID-19 Outcomes Among Black and White Patients With Cancer.** *JAMA Network Open.* 2022 Mar 1;5(3):e224304. doi: [10.1001/jamanetworkopen.2022.4304](https://doi.org/10.1001/jamanetworkopen.2022.4304). PMID: 35344045; PMCID: PMC8961318.
12. Rubinstein SM*, Bhutani D*, Lynch RC*, Hsu CY, Shyr Y, Advani S, Mesa RA, Mishra S, Mundt DP, Shah DP, Sica RA, Stockerl-Goldstein KE, Stratton C, Weiss M, Beeghly-Fadiel A, Accordini M, Assouline SE, Awosika J, Bakouny Z, Bashir B, Berg S, Bilen MA, Castellano CA, Cogan JC, Kc D, Friese CR, Gupta S, Hausrath D, Hwang C, Johnson NA, Joshi M, Kasi A, Klein EJ, Koshkin VS, Kuderer NM, Kwon DH, Labaki C, Latif T, Lau E, Li X, Lyman GH, McKay RR, Nagaraj G, Nizam A, Nonato TK, Olszewski AJ, Polimera HV, Portuguese AJ, Puc MM, Razavi P, Rosovski R, Schmidt A, Shah SA, Shastri A, Su C, Torka P, Wise-Draper TM, Zubiri L, Warner JL*, Thompson MA*. **Patients recently treated for B-lymphoid malignancies show increased risk of severe COVID-19: a CCC19 registry analysis.** *Blood Cancer Discovery.* 2022 May 5;3(3):181-193. doi: [10.1158/2643-3230.BCD-22-0013](https://doi.org/10.1158/2643-3230.BCD-22-0013). PMID: 35262738. PMCID: PMC9355598.
13. Wagner MJ, Hennessy C, Beeghly A, French B, Shah DP, Croessmann S, Vilar-Compte D, Ruiz-Garcia E, Ingham M, Schwartz GK, Painter CA, Chugh R, Fecher L, Park C, Zamulko O, Trent JC, Subbiah V, Khaki AR, Tachiki L, Nakasone ES, Loggers ET, Labaki C, Saliby RM, McKay RR, Ajmera A, Griffiths EA, Puzanov I, Tap WD, Hwang C, Tejwani S, Jhawar SR, Hayes-Lattin B, Wulff-Burchfield E, Kasi A, Reuben DY, Nagaraj G, Joshi M, Polimera H, Kulkarni AA, Esfahani K, Kwon DH, Paoluzzi L, Bilen MA, Durbin EB, Grivas P, Warner JL, Davis EJ; **COVID-19 and Cancer Consortium. Demographics, Outcomes, and Risk Factors for Patients with Sarcoma and COVID-19: A CCC19-Registry Based Retrospective Cohort Study.** *Cancers (Basel).* 2022 Sep 5;14(17):4334. doi: [10.3390/cancers14174334](https://doi.org/10.3390/cancers14174334). PMID: 36077869; PMCID: PMC9454925.
14. Bakouny Z*, Labaki C*, Grover P, Awosika J, Gulati S, Hsu CY, Alimohamed SI, Bashir B, Berg S, Bilen MA, Bowles D, Castellano C, Desai A, Elkrief A, Eton OE, Fecher LA, Flora D, Galsky MD, Gatti-Mays ME, Gesenhues A, Glover MJ, Gopalakrishnan D, Gupta S, Halfdanarson TR, Hayes-Lattin B, Hendawi M, Hsu E, Hwang C, Jandarov R, Jani C, Johnson DB, Joshi M, Khan H, Khan SA, Knox N, Koshkin VS, Kulkarni AA, Kwon DH, Matar S, McKay RR, Mishra S, Moria FA, Nizam A, Nock NL, Nonato TK, Panasci J, Pomerantz L, Portuguese AJ, Provenzano D, Puc M, Rao YJ, Rhodes TD, Riely GJ, Ripp JJ, Rivera AV, Ruiz-Garcia E, Schmidt AL, Schoenfeld AJ, Schwartz GK, Shah SA, Shaya J, Subbiah S, Tachiki LM, Tucker MD, Valdez-Reyes M, Weissmann LB, Wotman MT, Wulff-Burchfield EM, Xie Z, Yang YJ, Thompson MA, Shah DP, Warner JL, Shyr Y, Choueiri TK*, Wise-Draper TM*; COVID-19 and Cancer Consortium. **Interplay of Immunosuppression and Immunotherapy Among Patients with Cancer and COVID-19.** *JAMA Oncology.* 2023 Jan 1;9(1):128-134. doi: [10.1001/jamaoncol.2022.5357](https://doi.org/10.1001/jamaoncol.2022.5357). PMID: 36326731. PMCID: PMC9634600.



15. Choueiri TK*, Labaki C*, Bakouny Z*, Hsu C-Y, Schmidt AL, de Lima Lopes G, Hwang C, Singh SRK, Jani C, Weissmann LB, Griffiths EA, Halabi S, Wu U, Berg S, O'Connor TE, Wise-Draper TM, Panagiotou OA, Klein EJ, Joshi M, Yared F, Santos Dutra M, Gatson NTN, Blau S, Singh H, Nanchal R, McKay RR, Nonato TK, Quinn R, Rubinstein SM, Puc M, Mavromatis BH, Vikas P, Faller B, Zaren HA, Del Prete S, Russell K, Reuben DY, Accordino MK, Singh H, Friese CR, Mishra S, Rivera DR*, Shyr Y*, Farmakiotis D*, Warner JL*. **Breakthrough SARS-CoV-2 infections among patients with cancer following two and three doses of COVID-19 mRNA vaccines: a retrospective observational study from the COVID-19 and Cancer Consortium.** *The Lancet Regional Health – Americas.* 2023 Mar;19: 100445. doi: [10.1016/j.lana.2023.100445](https://doi.org/10.1016/j.lana.2023.100445) PMID: 36818595. PMCID: PMC9925160.
16. Gayathri Nagaraj*, Shaveta Vinayak*, Ali Raza Khaki*, Tianyi Sun, Nicole M. Kuderer, David M. Aboulafia, Jared D. Acoba, Joy Awosika, Ziad Bakouny, Nicole B. Balmaceda, Ting Bao, Babar Bashir, Stephanie Berg, Mehmet A. Bilen, Poorva Bindal, Sibel Blau, Brianne E. Bodin, Hala T. Borno, Cecilia Castellano, Horyun Choi, John Deeken, Aakash Desai, Natasha Edwin, Lawrence E. Feldman, Daniel B. Flora, Christopher R. Friese, Matthew D. Galsky, Cyndi J. Gonzalez, Petros Grivas, Shilpa Gupta, Marcy Haynam, Hannah Heilman, Dawn L. Hershman, Clara Hwang, Chinmay Jani, Sachin R. Jhavar, Monika Joshi, Virginia Kaklamani, Elizabeth J. Klein, Natalie Knox, Vadim S. Koshkin, Amit A. Kulkarni, Daniel H. Kwon, Chris Labaki, Philip E. Lammers, Kate I. Lathrop, Mark A. Lewis, Xuanyi Li, Gilberto de Lima Lopes, Gary H. Lyman, Della F. Makower, Abdul-Hai Mansoor, Merry-Jennifer Markham, Sandeep H. Mashru, Rana R. McKay, Ian Messing, Vasil Mico, Rajani Nadkarni, Swathi Namburi, Ryan H. Nguyen, Taylor Kristian Nonato, Tracey Lynn O'Connor, Orestis A. Panagiotou, Kyu Park, Jaymin M. Patel, Kanishka GopikaBimal Patel, Jeffrey Peppercorn, Hyma Polimera, Matthew Puc, Yuan James Rao, Pedram Razavi, Sonya A. Reid, Jonathan W. Riess, Donna R. Rivera, Mark Robson, Suzanne J. Rose, Atlantis D. Russ, Lidia Schapira, Pankil K. Shah, M. Kelly Shanahan, Lauren C. Shapiro, Melissa Smits, Daniel G. Stover, Mitrianna Streckfuss, Lisa Tachiki, Michael A. Thompson, Sara M. Tolaney, Lisa B. Weissmann, Grace Wilson, Michael T. Wotman, Elizabeth M. Wulff-Burchfield, Sanjay Mishra, Benjamin French, Jeremy L. Warner, Maryam B. Lustberg*, Melissa K. Accordino*, Dimpay P. Shah*. **Clinical Characteristics, Racial Inequities, and Outcomes in Patients with Breast Cancer and COVID-19: A COVID-19 and Cancer Consortium (CCC19) Cohort Study.** *medRxiv.* doi: [10.1101/2023.03.09.23287038](https://doi.org/10.1101/2023.03.09.23287038).
17. Johnson DB, Atkins MB, Hennessy C, Wise-Draper T, Heilman H, Awosika J, Bakouny Z, Labaki C, Saliby RM, Hwang C, Singh SRK, Balanchivadze N, Friese CR, Fecher LA, Yoon JJ, Hayes-Lattin B, Bilen MA, Castellano CA, Lyman GH, Tachiki L, Shah SA, Glover MJ, Flora DB, Wulff-Burchfield E, Kasi A, Abbasi SH, Farmakiotis D, Viera K, Klein EJ, Weissman LB, Jani C, Puc M, Fahey CC, Reuben DY, Mishra S, Beeghly-Fadiel A, French B, Warner JL; COVID-19 and Cancer Consortium. **Impact of COVID-19 in patients on active melanoma therapy and with history of melanoma.** *BMC Cancer.* 2023 Mar 23;23(1):265. doi: [10.1186/s12885-023-10708-6](https://doi.org/10.1186/s12885-023-10708-6). PMID: 36949413.

Public Datasets

1. Nagaraj G, Khaki A, Shah D. **COVID-19 and Cancer Consortium (CCC19) breast cancer and racial disparities outcomes study.** *Dryad.* 2023 Feb 20. doi: [10.5061/dryad.1g1jwsv10](https://doi.org/10.5061/dryad.1g1jwsv10).

Current and Past Funding

We would like to acknowledge the support of current and past funders, who have made this work possible: American Cancer Society; Hope Foundation for Cancer Research; International Association for the Study of Lung Cancer; Melanoma Research Foundation; National Institutes of Health; North American Thrombosis Forum